文献速递血栓与止血

获得性血友病A中抗重组猪FVIII交叉反应抑制物的研究

Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study.
PubMed 文献 · J Thromb Haemost · 2019-09-12

该前瞻性观察性队列研究GTH-AH 01/2010分析了70例获得性血友病A患者的基线样本,发现44%的患者存在部分抑制重组猪FVIII的交叉反应抑制物,且抗人FVIII滴度>100 BU/mL时交叉反应可能性高达97%。

要点

  • 44%的AHA患者存在抗rpFVIII交叉反应抑制物,滴度多≤5 BU/mL。
  • 抗人FVIII滴度>100 BU/mL预测交叉反应可能性为97%。
  • 仅针对C2结构域的抑制物交叉反应罕见(6%)。

核心结论

  • 选择AHA出血患者治疗方案时应考虑交叉反应抑制物。
  • 抗人FVIII滴度>100 BU/mL的患者中交叉反应常见。

研究设计与样本

  • 前瞻性观察性队列研究GTH-AH 01/2010,纳入70例获得性血友病A患者的基线样本。
  • 采用改良Nijmegen-Bethesda法检测抗人FVIII和抗rpFVIII抑制物,ELISA检测抗人FVIII结构域反应性。

主要发现

  • 所有样本均存在抗人FVIII抑制物,滴度范围为0.7-3891 BU/mL。
  • 31/70例(44%)患者的抑制物部分抑制rpFVIII,抗rpFVIII滴度范围为0.5-471 BU/mL,多数患者抗rpFVIII滴度≤5 BU。
  • 有交叉反应抑制物的患者较无交叉反应者抗人FVIII滴度显著更高(27.8 vs 5.4 BU/mL),基线FVIII活性更低(<1 vs 2.6 IU/dL)。
  • 涉及C1结构域的抑制物抗rpFVIII与抗人滴度比值最高;仅与C2结构域反应的抑制物交叉反应罕见(6%)。
  • 抗人FVIII滴度>100 BU/mL预测交叉反应可能性为97%,<3.8 BU/mL预测无交叉反应可能性为90%。

关键数值与推荐

  • 抗人FVIII滴度>100 BU/mL预测交叉反应可能性为97%。
  • 抗人FVIII滴度<3.8 BU/mL预测无交叉反应可能性为90%。

临床怎么用

  • 对于AHA出血患者,选择治疗时应考虑交叉反应抑制物的可能性。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Recombinant porcine factor VIII (rpFVIII, OBI-1, susoctocog alfa) is used for the treatment of acute bleeds in patients with acquired hemophilia A (AHA). Inhibitors in AHA can sometimes cross-react with rpFVIII. OBJECTIVES: To assess the frequency, strength, and determinants of cross-reactivity. PATIENTS/METHODS: Baseline samples from 70 patients of the prospective, observational cohort study GTH-AH 01/2010 were assessed for anti-human FVIII and anti-rpFVIII inhibitors using modified Nijmegen-Bethesda assays, as well as anti-human FVIII domain reactivity using enzyme-linked immunoassay (ELISA). RESULTS: Anti-human FVIII inhibitors were present in all samples ranging between 0.7 and 3891 Bethesda Units (BU)/mL. Inhibitors from 31 of 70 patients (44%) partially inhibited rpFVIII with anti-rpFVIII titers ranging between 0.5 and 471 BU/mL. Anti-rpFVIII titers were ≤5 BU in most patients. Patients with cross-reacting inhibitors, as compared to patients without, had significantly higher anti-human FVIII titers (27.8 versus 5.4 BU/mL) and lower baseline FVIII activity (<1 versus 2.6 IU/dL). The ratio between anti-rpFVIII to anti-human titers was highest for inhibitors involving the C1 domain. Cross-reactivity was very rare, if inhibitors reacted only with the C2 domain of FVIII (6%). An anti-human FVIII titer of >100 BU/mL predicted cross-reactivity with 97% likelihood, whereas an anti-human FVIII titer of <3.8 BU/mL predicted absent cross-reactivity with 90% likelihood. CONCLUSION: Cross-reacting inhibitors should be considered when choosing a treatment for bleeding patients with AHA. Cross-reactivity is frequent in patients with anti-human FVIII titers of >100 BU/mL.

来源:J Thromb Haemost,查看原文。版权归原作者所有。

引用

  1. Türkantoz H, Königs C, Knöbl P, et al. Cross-reacting inhibitors against recombinant porcine factor VIII in acquired hemophilia A: Data from the GTH-AH 01/2010 Study. J Thromb Haemost. 2019. PMID: 31448877. doi:10.1111/jth.14618

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。